Position Papers, Reports & Guidelines
This page lists white papers, best practices, guidelines, and other relevant documents for fight against counterfeit medicines.
-
AIM Anti-Counterfeiting Committee. Customs and Rightholders: The best of partners need the best of practices. Brussels, June 2007.
-
AIPM/CIPR. "Action Plan to Fight Counterfeit Medicines in Russia." The Association of International Pharmaceutical Manufacturers and Coalition for Intellectual Property Rights, two groups fighting counterfeiting in Russia.
- American and Canadian Pharmacists Associations. Joint Statement of American and Canadian Pharmacists' Associations on Importation. (2003)
- American Society of Health-System Pharmacists. The Council on Professional Affairs, which deals with issues of pharmacy practice standards and patient care, passed policy recommendations on pharmaceutical counterfeiting. See 2004 Policy Recommendations.
- CEFIC/APIC Position on Counterfeiting of APIs. API stands for active pharmaceutical ingredient. In order to make sure that medicines are safe for patients, the Active Pharmaceutical Ingredient Committee (APIC) works to insure that APIs are manufactured in compliance with appropriate pharmaceutical regulations.
- EAEPC Good Parallel Distribution Practice Guidelines for Medicinal Products. From the European Association of Euro-Pharmaceutical Companies.
- EFPIA's Paper on Counterfeit Medicines.
- Healthcare Distribution Management Association (HDMA). HDMA's mission is to secure safe and effective distribution of healthcare products, create and exchange industry knowledge affecting the future of distribution management, and influence standards and business processes that produce efficient healthcare commerce. HDMA has been very active in stimulating anticounterfeiting action and in the adoption of the ePC. Its Best Practices Guidelines for wholesalers and distributors has been largely incorporated into the NABP rules.
- Health Industry Group Purchasing Association (HIGPA)—HIGPA recently adopted a practice guideline Integrity of the Pharmaceutical Supply Chain: Product Sourcing and Patient Safety.
- International Federation of Pharmaceutical Manufacturers and Associations homepage on Counterfeit Drugs.
- International Federation of Pharmaceutical Wholesalers statement on anti-counterfeiting policy (September 2004).
- National Association of Boards of Pharmacy. The NABP represents the state Boards of Pharmacy, which regulate pharmacies, distributors, and wholesalers. See their Model Rules for Wholesale Licensure.
- Pharmaceutical Research and Manufacturers of America. In 2003, PhRMA adopted a five-point plan to combat counterfeit drugs. Available here.
- Pharmaceutical Security Institute. PSI's top priority, to protect the public health, will be achieved by the disruption and dismantling of those criminal groups involved in counterfeit pharmaceuticals. Information concerning the activities of these groups is the cornerstone of successful disruptions. By promptly sharing this information with the appropriate authorities, enforcement actions can be immediately taken to safeguard public health.